A Phase II Trial of Nivolumab in Combination With Ipilimumab to Evaluate Efficacy and Safety Relapsed in Lung Cancer and to Evaluate Biomarkers Predictive for Response to Immune Checkpoint Inhibition
Latest Information Update: 04 Jul 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Non-small cell lung cancer; Small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms BIOLUMA
- 04 Jun 2024 Results(n=45) evaluating the combination therapy of nivolumab and ipilimumab in TMBhigh SCLC patients , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 08 Dec 2023 Status changed from active, no longer recruiting to completed.
- 18 Oct 2023 Planned End Date changed from 1 Sep 2023 to 1 Dec 2023.